These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 28819285)

  • 1. Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis.
    Gerboth S; Frittoli E; Palamidessi A; Baltanas FC; Salek M; Rappsilber J; Giuliani C; Troglio F; Rolland Y; Pruneri G; Kreutmair S; Pallavicini I; Zobel M; Cinquanta M; Minucci S; Gomez C; Santos E; Illert AL; Scita G
    Leukemia; 2018 Mar; 32(3):820-827. PubMed ID: 28819285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Bcr-Abl with the proto-oncogene Vav is implicated in activation of the Rac-1 pathway.
    Bassermann F; Jahn T; Miething C; Seipel P; Bai RY; Coutinho S; Tybulewicz VL; Peschel C; Duyster J
    J Biol Chem; 2002 Apr; 277(14):12437-45. PubMed ID: 11790798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abl-dependent tyrosine phosphorylation of Sos-1 mediates growth-factor-induced Rac activation.
    Sini P; Cannas A; Koleske AJ; Di Fiore PP; Scita G
    Nat Cell Biol; 2004 Mar; 6(3):268-74. PubMed ID: 15039778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells.
    Mandanas RA; Leibowitz DS; Gharehbaghi K; Tauchi T; Burgess GS; Miyazawa K; Jayaram HN; Boswell HS
    Blood; 1993 Sep; 82(6):1838-47. PubMed ID: 7691239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CIIA functions as a molecular switch for the Rac1-specific GEF activity of SOS1.
    Hwang HS; Hwang SG; Cho JH; Chae JS; Yoon KW; Cho SG; Choi EJ
    J Cell Biol; 2011 Oct; 195(3):377-86. PubMed ID: 22042618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vav3 collaborates with p190-BCR-ABL in lymphoid progenitor leukemogenesis, proliferation, and survival.
    Chang KH; Sanchez-Aguilera A; Shen S; Sengupta A; Madhu MN; Ficker AM; Dunn SK; Kuenzi AM; Arnett JL; Santho RA; Agirre X; Perentesis JP; Deininger MW; Zheng Y; Bustelo XR; Williams DA; Cancelas JA
    Blood; 2012 Jul; 120(4):800-11. PubMed ID: 22692505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical Requirement of SOS1 for Development of BCR/ABL-Driven Chronic Myelogenous Leukemia.
    Gómez C; Garcia-Navas R; Baltanás FC; Fuentes-Mateos R; Fernández-Medarde A; Calzada N; Santos E
    Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac.
    Skorski T; Wlodarski P; Daheron L; Salomoni P; Nieborowska-Skorska M; Majewski M; Wasik M; Calabretta B
    Proc Natl Acad Sci U S A; 1998 Sep; 95(20):11858-62. PubMed ID: 9751755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sos1 Regulates Macrophage Podosome Assembly and Macrophage Invasive Capacity.
    Baruzzi A; Remelli S; Lorenzetto E; Sega M; Chignola R; Berton G
    J Immunol; 2015 Nov; 195(10):4900-12. PubMed ID: 26447228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of rac-guanine nucleotide exchange activity of Ras-GRF1/CDC25(Mm) following phosphorylation by the nonreceptor tyrosine kinase Src.
    Kiyono M; Kaziro Y; Satoh T
    J Biol Chem; 2000 Feb; 275(8):5441-6. PubMed ID: 10681520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine phosphorylation of p120cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase.
    Jain SK; Langdon WY; Varticovski L
    Oncogene; 1997 May; 14(18):2217-28. PubMed ID: 9174058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation.
    Sahay S; Pannucci NL; Mahon GM; Rodriguez PL; Megjugorac NJ; Kostenko EV; Ozer HL; Whitehead IP
    Oncogene; 2008 Mar; 27(14):2064-71. PubMed ID: 17922031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation.
    Gishizky ML; Cortez D; Pendergast AM
    Proc Natl Acad Sci U S A; 1995 Nov; 92(24):10889-93. PubMed ID: 7479904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and Structure-Based Optimization of Benzimidazole-Derived Activators of SOS1-Mediated Nucleotide Exchange on RAS.
    Hodges TR; Abbott JR; Little AJ; Sarkar D; Salovich JM; Howes JE; Akan DT; Sai J; Arnold AL; Browning C; Burns MC; Sobolik T; Sun Q; Beesetty Y; Coker JA; Scharn D; Stadtmueller H; Rossanese OW; Phan J; Waterson AG; McConnell DB; Fesik SW
    J Med Chem; 2018 Oct; 61(19):8875-8894. PubMed ID: 30205005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis.
    Qiu X; Guo G; Chen K; Kashiwada M; Druker BJ; Rothman PB; Chen JL
    Neoplasia; 2012 Jun; 14(6):547-58. PubMed ID: 22787435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential motility of p190bcr-abl- and p210bcr-abl-expressing cells: respective roles of Vav and Bcr-Abl GEFs.
    Daubon T; Chasseriau J; El Ali A; Rivet J; Kitzis A; Constantin B; Bourmeyster N
    Oncogene; 2008 Apr; 27(19):2673-85. PubMed ID: 18059343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis.
    Thomas EK; Cancelas JA; Zheng Y; Williams DA
    Leukemia; 2008 May; 22(5):898-904. PubMed ID: 18354486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
    Zhang X; Ren R
    Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of guanine nucleotide exchange and Rac-mediated signaling revealed by a dominant negative trio mutant.
    Debreceni B; Gao Y; Guo F; Zhu K; Jia B; Zheng Y
    J Biol Chem; 2004 Jan; 279(5):3777-86. PubMed ID: 14597635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depression of oncogenecity by dephosphorylating and degrading BCR-ABL.
    Gao M; Huang ZL; Tao K; Xiao Q; Wang X; Cao WX; Xu M; Hu J; Feng WL
    Oncotarget; 2017 Jan; 8(2):3304-3314. PubMed ID: 27926512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.